May 2021: Today we say “farewell” to three amazing students: Jared Miller, Brittany Brems, and Caitlin Vitro have spent the last 2-3 years in our research lab and have grown into phenomenal scientists. They will be each be entering PhD programs this fall at opposite corners of the country: Scripps, Northeastern, and UNC Chapel Hill, respectively. I have no doubt they will be enormously successful. But we will miss them! Congratulations and best of luck!
March 2021: Our work on legumain-cleavable ADC linkers was just published in Bioconjugate Chemistry! Congrats in particular to Jared Miller, the first author, who did a lot of the heavy-lifting for this paper as an undergrad in my lab. He will be joining Scripps Research Institute this fall! And a special “thank you” to Takeda Pharmaceuticals who funded the majority of this work! https://doi.org/10.1021/acs.bioconjchem.1c00124
January 2021: Welcome to two new undergraduate members of our team: Emma Deyoung and Daniel Wheeler!
July 2020: We are excited to have just purchased a new Waters triple quadrupole mass spectrometer! This instrument will be invaluable for studying ADC metabolism and catabolism.
June 2020: The Tumey lab has received a 3-year $450,000 NIH grant in collaboration with Dr. Tracy Brooks (PI) to develop antibody-DNA conjugates for the treatment of non-Hodgkin’s Lymphoma. Specifically, we are focusing on delivery of a short interfering DNA that blocks the expression of the oncogene MYC.
April 2020: Our Angewandte Chemie paper entitled “Expanding the Versatility of Microbial Transglutaminase Using α‐Effect Nucleophiles as Noncanonical Substrates” was just accepted for publication! This paper describes the use of hydrazines, hydrazides, and hydroxylamines as transglutaminase substrates. Congratulations in particular to Tak Ian Choi as the first author on this paper!
February 2020: We are excited to have just received a funding notification for our recent R15 grant application! The NIH award is a 3-year $450,480 grant from the NIAID entitled “Cell-specific blockage of TLR activation: A new strategy for addressing inflammatory disorders.” The goal of this project is to develop targeted therapeutics that selectively inhibit the innate immune response through inhibition of a key enzyme in the TLR signaling pathway.
January 2020: Welcome to two new members of our group, Justin Howe and Katherine Leong. Both Justin and Katherine are sophomore chemistry students at BU.
December 2019: Five abstracts from our group were recently accepted for the upcoming national meeting of the American Chemical Society in Philadelphia! (link)